The role of bisphosphonates in breast and prostate cancers.

@article{Brown2004TheRO,
  title={The role of bisphosphonates in breast and prostate cancers.},
  author={Janet E Brown and Helen L. Neville-Webbe and Robert Coleman},
  journal={Endocrine-related cancer},
  year={2004},
  volume={11 2},
  pages={
          207-24
        }
}
Bisphosphonate drugs are a group of pyrophosphate analogues which bind avidly to hydroxyapatite bone mineral surfaces and their major action is to inhibit osteoclast activity and thus bone resorption. In oncology, their role in metastatic bone disease is well established, but there is increasing interest in their potential role in preventing and treating cancer-induced bone loss and their possible anti-tumour effects. Metastatic bone disease is associated with a variety of skeletal… Expand

Paper Mentions

Interventional Clinical Trial
Zoledronic acid (Zometa) belongs to a class of drugs called bisphosphonates. Bisphosphonates are used in bone metastases to keep the cancerous lesion under control in the bone and to… Expand
ConditionsBone Metastases, Breast Cancer, Lung Cancer, (+1 more)
InterventionDrug
Zoledronic acid in the management of metastatic bone disease
TLDR
In vivo preclinical and preliminary clinical data suggest that bisphosphonates may prevent cancer treatment-induced bone loss and the onset of malignant bone disease in patients with early-stage cancer. Expand
Exploring the anti-tumour activity of bisphosphonates in early breast cancer.
TLDR
The potential synergistic anti-tumour effects of the sequential treatment of neoadjuvant chemotherapy followed by zoledronic acid in a randomised phase II study evaluating biological endpoints including apoptosis, proliferation and angiogenesis in patients with breast cancer is explored. Expand
Anti-tumour activity of zoledronic acid.
TLDR
The future challenge is to focus on optimizing dosing regimens and drug combinations to maximize the anti-tumour potential of zoledronic acid and to take advantage of the observed synergy with standard neoplastic agents. Expand
Prolonged Efficacy of a Single Dose of the Bisphosphonate Zoledronic Acid
TLDR
A single dose of zoledronic acid in patients with low BMD results in a sustained increase in BMD and a corresponding decrease in bone resorption, which may have clinical benefits in terms of convenience, reduced toxicity, improved compliance, and cost. Expand
Is there a role for ibandronate in the treatment of prostate cancer patients with bony metastases?
TLDR
Preliminary data emerging from small Phase II studies suggests ibandronate may provide a therapeutic alternative for the treatment of metastatic prostate cancer when zoledronic acid is deemed unsuitable. Expand
Teletherapy and radiopharmaceutical therapy of painful bone metastases.
TLDR
There will be 3 radiopharmaceuticals available in the United States that can reduce or relieve bone pain caused by osteoblastic metastases with apparently equal efficacy, but, given alone, none prolong life. Expand
Mechanism of Action, Pharmacokinetic and Pharmacodynamic Profile, and Clinical Applications of Nitrogen-containing Bisphosphonates
  • D. Kimmel
  • Medicine
  • Journal of dental research
  • 2007
TLDR
Nitrogen-containing bisphosphonates (nBPs) are bone-specific agents that inhibit farnesyl diphosphate synthase that are the most efficacious drugs available for these diseases, reducing osteoporotic fracture risk by 50–60% in persons with low bone mass or prior osteop orotic fracture, and SREs by one-third in cancer patients. Expand
Bisphosphonates in multiple myeloma: a network meta-analysis.
TLDR
Whether adding bisphosphonates to standard therapy in MM improves OS and progression-free survival (PFS), and decreases skeletal-related morbidity, is investigated. Expand
Bisphosphonates in multiple myeloma: an updated network meta-analysis.
TLDR
Results from network meta-analyses showed evidence of a benefit for OS with zoledronate compared with etidronate but limited evidence of an effect on PFS, as well as substantial heterogeneity among the included RCTs for OS. Expand
The bisphosphonate zoledronic acid has antimyeloma activity in vivo by inhibition of protein prenylation
TLDR
These studies provide clear evidence that N‐BPs have direct antitumor effects in plasma cell tumors in vivo and this is executed by a molecular mechanism similar to that observed in osteoclasts. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 158 REFERENCES
The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel
TLDR
It is suggested that, in addition to inhibiting bone resorption, zoledronic acid has a direct anti-tumour activity on breast cancer cells in vitro and the commonly used anti-neoplastic agent, paclitaxel, potentiates the anti-Tumour effects of zoledronics acid. Expand
Effects of the bisphosphonate olpadronate in patients with carcinoma of the prostate metastatic to the skeleton.
TLDR
It was observed that intravenous therapy was associated with a decrease in bone pain in 76% of patients and a reduction in the use of analgesics, and the clinical response appeared to parallel the biochemical changes in bone resorption. Expand
The bisphosphonate pamidronate is a potent inhibitor of human osteosarcoma cell growth in vitro
TLDR
Results suggest that pamidronate may be a useful agent for the treatment of patients with osteosarcoma, as it inhibited cell growth in a time- and dose- dependent manner and decreased proliferation in a dose-dependent manner. Expand
Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice.
TLDR
It is demonstrated that risedronate decreases metastatic MDA-231 breast cancer burden selectively in bone, as well as suppresses progression of established osteolytic lesions and prevents the development of new osteolytics lesions; thus, the data suggest that inhibition of osteoclastic bone resorption may be a useful adjunctive therapy for the treatment of cancers that have colonized in bone. Expand
The New Bisphosphonate, Zometa® (Zoledronic Acid), Decreases Skeletal Complications in Both Osteolytic and Osteoblastic Lesions: A Comparison to Pamidronate
TLDR
Zoledonic acid is the first bisphosphonate to demonstrate efficacy in both lytic and blastic disease and was well tolerated with a safety profile similar to other IV bisph phosphonates. Expand
Bisphosphonate therapy for patients with breast carcinoma
TLDR
Among patients with skeletal metastases from breast carcinoma, a recent retrospective analysis demonstrated that patients with disease confined to the skeleton were at greater risk of pathologic fractures compared with patients who had additional extraosseous disease. Expand
Reduction in new metastases in breast cancer with adjuvant clodronate treatment.
TLDR
Clodronate can reduce the incidence and number of new bony and visceral metastases in women with breast cancer who are at high risk for distant metastases. Expand
Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group.
BACKGROUND Bisphosphonates such as pamidronate disodium inhibit osteoclast-induced bone resorption associated with cancer that has metastasized to bone. METHODS Women with stage IV breast cancerExpand
Bisphosphonate treatment inhibits the growth of prostate cancer cells.
TLDR
The intriguing possibility that the observed clinical utility of bisphosphonates in managing skeletal metastases may in part derive from direct inhibition of prostate cancer cell growth in the bone microenvironment is raised. Expand
Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro.
TLDR
The previously unrecognized effect of bisphosphonates on tumor-induced osteoclastic resorption makes these agents suitable for earlier pharmacologic intervention in patients with breast cancer at risk of developing bone metastases. Expand
...
1
2
3
4
5
...